Improved Discount Helps Lilly Secure English Funding For Verzenios

CDK4/6 Inhibitor Ibrance Has Not Yet Been Reappraised by NICE

 
• By Neena Brizmohun
NICE says Verzenios is a cost-effective use of NHS resources in the second-line breast cancer setting • Source: Alamy

More from United Kingdom

More from Europe